Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Helen X. Chen"'
Autor:
Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-15 (2022)
Abstract Background Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametini
Externí odkaz:
https://doaj.org/article/dfe80954e86a42808631f0fc9dd65391
Autor:
Maria L. Ascierto, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously receiv
Externí odkaz:
https://doaj.org/article/89bb1f6f1879436cad94a0ed44bd3547
Autor:
Howard Streicher, Elad Sharon, Razelle Kurzrock, Young Kwang Chae, Benjamin Tan, Megan Othus, Christine McLeod, Charles Blanke, Helen X Chen, Sandip P Patel, Gabby Lopez, Tridu Huynh, Timothy Kuzel, Christopher W Ryan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Objectives Multiple common cancers benefit from immunotherapy; however, less is known about efficacy in rare tumors. We report the results of the adrenocortical carcinoma cohort of NCI/SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Externí odkaz:
https://doaj.org/article/200c10085aef41019eb8269d72020f4d
Autor:
Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to upfront treatment with immune checkpoint inhibitors (ICIs) or progressive/recurrent disease occ
Externí odkaz:
https://doaj.org/article/fd73b0fbb8884f60901ba9db5264d2cd
Autor:
Livius Penter, Yang Liu, Jacquelyn O. Wolff, Lin Yang, Len Taing, Aashna Jhaveri, Jackson Southard, Manishkumar Patel, Nicole M. Cullen, Kathleen L. Pfaff, Nicoletta Cieri, Giacomo Oliveira, Seunghee Kim-Schulze, Srinika Ranasinghe, Rebecca Leonard, Taylor Robertson, Elizabeth A. Morgan, Helen X. Chen, Minkyung H. Song, Magdalena Thurin, Shuqiang Li, Scott J. Rodig, Carrie Cibulskis, Stacey Gabriel, Pavan Bachireddy, Jerome Ritz, Howard Streicher, Donna S. Neuberg, F. Stephen Hodi, Matthew S. Davids, Sacha Gnjatic, Kenneth J. Livak, Jennifer Altreuter, Franziska Michor, Robert J. Soiffer, Jacqueline S. Garcia, Catherine J. Wu
Publikováno v:
Blood. 141:1817-1830
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026 study te
Autor:
Meghan J. Mooradian, James M. Cleary, Anita Giobbie‐Hurder, Lancia N. F. Darville, Aparna Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X. Chen, Susan Percy Ivy, Keiran S. M. Smalley, John M. Koomen, Ryan J. Sullivan
Publikováno v:
Cancer. 129:1904-1918
Autor:
Steven G. DuBois, Mark D. Krailo, Julia Glade-Bender, Allen Buxton, Nadia Laack, R. Lor Randall, Helen X. Chen, Nita L. Seibel, Matthew Boron, Stephanie Terezakis, Christine Hill-Kayser, Andrea Hayes, Joel M. Reid, Lisa Teot, Dinesh Rakheja, Richard Womer, Carola Arndt, Stephen L. Lessnick, Brian D. Crompton, E. Anders Kolb, Heike Daldrup-Link, Eric Eutsler, Damon R. Reed, Katherine A. Janeway, Richard G. Gorlick
Publikováno v:
Journal of Clinical Oncology. 41:2098-2107
PURPOSE Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addit
Autor:
Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 41:186-197
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory a
Autor:
Amanda N. Ruggieri, Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, Helen X. Chen, Brian M. Olson, Chrystal M. Paulos, Bassel F. El-Rayes, Shishir K. Maithel, Nilofer S. Azad, Gregory B. Lesinski
Publikováno v:
Clin Cancer Res
Purpose: Biliary tract cancers (BTC) are aggressive malignancies refractory to chemotherapy and immunotherapy. MEK inhibition (MEKi)-based regimens may have utility in this disease when combined with PD-L1 blockade. We hypothesize that dual MEK/PD-L1
Autor:
Gregory B. Lesinski, Nilofer S. Azad, Shishir K. Maithel, Bassel F. El-Rayes, Chrystal M. Paulos, Brian M. Olson, Helen X. Chen, Elad Sharon, Yuan Liu, Subir Goyal, Mark Yarchoan, Amanda N. Ruggieri
Supplementary Table from Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6fdaa8375934267afa17540e47cb54
https://doi.org/10.1158/1078-0432.22489040.v1
https://doi.org/10.1158/1078-0432.22489040.v1